| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance
|
Tobalina, L.
|
|
|
32 |
1 |
p. 103-112
|
artikel
|
| 2 |
Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer: the TNT trial
|
Sipos, O.
|
|
|
32 |
1 |
p. 58-65
|
artikel
|
| 3 |
Cautionary tails
|
Del Paggio, J.C.
|
|
|
32 |
1 |
p. 20-22
|
artikel
|
| 4 |
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|
Eichhorst, B.
|
|
|
32 |
1 |
p. 23-33
|
artikel
|
| 5 |
Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial
|
Shi, M.
|
|
|
32 |
1 |
p. 85-96
|
artikel
|
| 6 |
Corrigendum to “Inhibiting fibroblast growth factor receptors in cancer – the next generation”
|
Schuler, M.
|
|
|
32 |
1 |
p. 126
|
artikel
|
| 7 |
COVID-19-associated pancytopenia can be self-limiting and does not necessarily warrant bone marrow biopsy for the purposes of SARS-CoV-2 diagnostics
|
Hersby, D.S.
|
|
|
32 |
1 |
p. 121-123
|
artikel
|
| 8 |
Data protection and research in the European Union: a major step forward, with a step back
|
Casali, P.G.
|
|
|
32 |
1 |
p. 15-19
|
artikel
|
| 9 |
Editorial Board
|
|
|
|
32 |
1 |
p. iii
|
artikel
|
| 10 |
Expanding the nanotherapeutic toolbox for non-small-cell lung cancer
|
Jee, J.
|
|
|
32 |
1 |
p. 9-11
|
artikel
|
| 11 |
Is there a role for novel TKI/ICI combinations in metastatic renal cell carcinoma? Definitely maybe
|
Meza, L.
|
|
|
32 |
1 |
p. 12-14
|
artikel
|
| 12 |
Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, a phase I clinical trial
|
Hiltbrunner, S.
|
|
|
32 |
1 |
p. 120-121
|
artikel
|
| 13 |
Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)
|
Fasching, P.A.
|
|
|
32 |
1 |
p. 49-57
|
artikel
|
| 14 |
Overall survival with 3 or 6 months of adjuvant chemotherapy in Italian TOSCA phase 3 randomised trial
|
Petrelli, F.
|
|
|
32 |
1 |
p. 66-76
|
artikel
|
| 15 |
Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial
|
Yamazaki, K.
|
|
|
32 |
1 |
p. 77-84
|
artikel
|
| 16 |
PARP inhibition in homologous-recombination-deficient early-stage breast cancer
|
Pusztai, L.
|
|
|
32 |
1 |
p. 4-5
|
artikel
|
| 17 |
Prognostic models: clinical impact now within reach
|
Bauer-Mehren, A.
|
|
|
32 |
1 |
p. 123-124
|
artikel
|
| 18 |
Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2
|
Marra, A.
|
|
|
32 |
1 |
p. 113-119
|
artikel
|
| 19 |
Side-effect management of chimeric antigen receptor (CAR) T-cell therapy
|
Schubert, M.-L.
|
|
|
32 |
1 |
p. 34-48
|
artikel
|
| 20 |
Table of Contents
|
|
|
|
32 |
1 |
p. i-ii
|
artikel
|
| 21 |
Thanks to referees 2020
|
|
|
|
32 |
1 |
p. 1-3
|
artikel
|
| 22 |
The cost–benefit ratio of a smile
|
Avanzini, F.
|
|
|
32 |
1 |
p. 124-125
|
artikel
|
| 23 |
TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma
|
Albiges, L.
|
|
|
32 |
1 |
p. 97-102
|
artikel
|
| 24 |
TOSCA—a delicious Swedish almond cake, an Italian opera and an Italian trial with important new data
|
Glimelius, B.
|
|
|
32 |
1 |
p. 6-8
|
artikel
|
Tijdschrift beschrijving